Stay updated on Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial

Sign up to get notified when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The website has been updated from version v2.10.2 to v2.10.3.
    Difference
    0.1%
    Check dated 2024-09-04T05:23:48.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The website has added new content, while the FDA Safety Alerts and Recalls section has been removed.
    Difference
    0.3%
    Check dated 2024-08-28T02:45:51.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.
    Difference
    0.1%
    Check dated 2024-08-13T23:29:37.000Z thumbnail image
  5. Check
    31 days ago
    No Change Detected
  6. Check
    45 days ago
    Change Detected
    Summary
    The study has expanded to include 29 locations, and the revision has been updated from v2.9.7 to v2.10.0.
    Difference
    0.5%
    Check dated 2024-07-23T15:10:43.000Z thumbnail image
  7. Check
    46 days ago
    Change Detected
    Summary
    A new Investigator Inquiry form has been added to the website.
    Difference
    0.2%
    Check dated 2024-07-22T13:51:53.000Z thumbnail image
  8. Check
    53 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T08:35:45.000Z thumbnail image

Stay in the know with updates to Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.